×
0 0 0 0 0 0 0.11013986013986 0.132867132867133
Stockreport

Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

INTERSECT ENT (XENT)  More Company Research Source: Business Wire
Last intersect ent earnings: 8/1 08:18 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intersectent.com/investor-relations
PDF Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. This press release features multimedia. View the full release here:http://www.businesswire.com/news/home/20171211005357/en/ Intersect ENT's SINUVA™ (mometasone furoate) Sinus Implant, a new in-office treatment option for recurrent nasal polyps. (Photo: Business Wire) Placed during a routine physician office visit, SINUVA expands into the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyp di [Read more]

IMPACT SNAPSHOT EVENT TIME: XENT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
XENT alerts
from News Quantified
Opt-in for
XENT alerts

from News Quantified
Opt-in for
XENT alerts

from News Quantified